Although the early clinical results of first-generation EGFR inhibitors are impressive, unfortunately, most NSCLC patients with activating mutations eventually develop acquired resistance to EGFR inhibitors within several months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.